All articles tagged with #cd47
AbbVie is terminating its agreement with I-Mab regarding the development and commercialization of certain CD47 antibodies and products. This decision comes after AbbVie had previously opted out of part of the pact last year. The termination of the agreement is based on program discontinuation and AbbVie's strategic decision.
Scientists have discovered a new mechanism by which the immune system eliminates cells lacking CD47 molecules, with dendritic cells directly killing these CD47-lacking T cells. This finding offers potential implications for cancer therapy, as it opens up the possibility of inducing cell death in cancer cells by modifying CD47. The study, conducted by researchers from Kobe University, sheds light on the previously unknown capability of dendritic cells to directly kill immune cells lacking CD47, providing a fresh perspective for future research and treatment strategies.